Advanced
  Home Compare Reports

Comparison with Similar Reports

Embolotherapy Market by Product (Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters), Indication (Oncology, Vascular, Aneurysm...

Publisher:        MarketsandMarkets

# of Pages:        222

Rating: 

1 User License $4,950

Publication Date:  May, 2021

Price:       $4,950 / User License




1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 31
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED FOR THE STUDY 33
1.4 CURRENCY USED FOR THE STUDY 33
1.5 STAKEHOLDERS 33
1.6 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.1.1 An indicative list of secondary sources 37
2.1.2 PRIMARY DATA 37
FIGURE 2 BREAKDOWN OF PRIMARIES: EMBOLOTHERAPY MARKET 38
2.2 MARKET ESTIMATION METHODOLOGY 38
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 39
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 39
2.2.2 PRODUCT-BASED MARKET ESTIMATION 40
FIGURE 4 MARKET SIZE ESTIMATION: EMBOLOTHERAPY MARKET 41
2.2.3 PRIMARY RESEARCH VALIDATION 41
2.3 DATA TRIANGULATION 42
FIGURE 5 DATA TRIANGULATION METHODOLOGY 42
2.4 RESEARCH ASSUMPTIONS 43
2.5 RESEARCH LIMITATIONS 43
3 EXECUTIVE SUMMARY 44
FIGURE 6 EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION) 44
FIGURE 7 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION) 45
FIGURE 8 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION) 45
FIGURE 9 EMBOLOTHERAPY MARKET SHARE, BY END USER, 2021 VS. 2026 46
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE EMBOLOTHERAPY MARKET 47
 
4 PREMIUM INSIGHTS 48
4.1 EMBOLOTHERAPY: MARKET OVERVIEW 48
FIGURE 11 THE RISING INCIDENCE OF CHRONIC DISEASES IS A KEY FACTOR DRIVING MARKET GROWTH 48
4.2 GEOGRAPHIC ANALYSIS: NORTH AMERICA EMBOLOTHERAPY MARKET, BY PRODUCT, 2021 VS 2026, (USD MILLION) 49
FIGURE 12 THE EMBOLIC AGENTS SEGMENT WILL WITNESS HIGH GROWTH IN THE NORTH AMERICA MARKET IN 2026 49
4.3 EMBOLOTHERAPY MARKET, BY APPLICATION, 2021 VS 2026, (USD MILLION) 50
FIGURE 13 THE LIVER CANCER SUBSEGMENT OF THE ONCOLOGY APPLICATION IS EXPECTED TO DOMINATE THE MARKET DURING THE FORECAST PERIOD 50
4.4 EMBOLOTHERAPY MARKET, BY REGION AND PROCEDURE 51
FIGURE 14 TRANSARTERIAL EMBOLIZATION (TAE) PROCEDURE SEGMENT TO HOLD A MAJOR SHARE OF THE ASIA PACIFIC MARKET 51
4.5 GEOGRAPHIC ANALYSIS: EMBOLOTHERAPY MARKET, BY END USER AND
REGION, 2021 VS. 2026 (USD MILLION) 51
FIGURE 15 AMBULATORY SURGICAL CENTERS SEGMENT TO WITNESS HIGH GROWTH IN EUROPE DURING THE FORECAST PERIOD 51
4.6 GEOGRAPHIC SNAPSHOT OF THE EMBOLOTHERAPY MARKET 52
FIGURE 16 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 17 EMBOLOTHERAPY MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Growing target patient population 54
TABLE 1 PRIMARY INCIDENCE OF LIVER CANCER AMONG MEN
AND WOMEN (2005 VS. 2030) 54
TABLE 2 GERIATRIC POPULATION, BY REGION (2015 VS. 2030) 55
5.2.1.2 Rising patient preference for minimally invasive procedures 55
5.2.1.3 Funding & investments by government and private organizations 55
5.2.1.4 Technological advancements in embolotherapy devices 56
5.2.1.5 Favorable reimbursement scenario for minimally invasive surgeries 57
TABLE 3 MEDICAL REIMBURSEMENT CPT CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2021) 57
TABLE 4 MEDICAL REIMBURSEMENT MS-DRG CODES FOR EMBOLIZATION PROCEDURES IN THE US (EFFECTIVE FROM JANUARY 2019) 58
5.2.2 RESTRAINTS 58
5.2.2.1 Lack of sufficient evidence & unfavorable regulatory scenario 58
5.2.2.2 Strong market positioning of alternative therapies 59
5.2.3 OPPORTUNITIES 60
5.2.3.1 Growth opportunities offered by emerging markets 60
5.2.3.2 Expanding applications of embolization devices 60
5.2.4 CHALLENGES 61
5.2.4.1 A dearth of skilled surgeons 61
5.2.4.2 High cost of embolization devices 61
5.3 VALUE CHAIN ANALYSIS 61
FIGURE 18 VALUE CHAIN ANALYSIS 62
5.4 ECOSYSTEM: EMBOLOTHERAPY MARKET 62
5.5 REGULATORY ANALYSIS 63
5.5.1 NORTH AMERICA 63
5.5.1.1 US 63
TABLE 5 US FDA: MEDICAL DEVICE CLASSIFICATION 63
TABLE 6 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
5.5.1.2 Canada 64
TABLE 7 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 64
FIGURE 19 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES 65
5.5.2 EUROPE 65
FIGURE 20 EUROPE: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES (MDR) 66
5.5.3 ASIA PACIFIC 67
5.5.3.1 Japan 67
TABLE 8 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA) 67
5.5.3.2 China 68
TABLE 9 CHINA: CLASSIFICATION OF MEDICAL DEVICES 68
5.5.3.3 India 69
5.6 IMPACT OF COVID-19 ON EMBOLOTHERAPY MARKET 70
TABLE 10 COVID-19 GUIDELINES FOR TRIAGE OF VASCULAR SURGERY PATIENTS 70
6 EMBOLOTHERAPY MARKET, BY PRODUCT 72
6.1 INTRODUCTION 73
TABLE 11 EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 73
6.2 EMBOLIC AGENTS 73
TABLE 12 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 74
TABLE 13 EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY REGION,
2019–2026 (USD MILLION) 74
TABLE 14 EMBOLIC AGENTS, BY TYPE 75
6.2.1 LIQUID EMBOLIC AGENTS 75
6.2.1.1 Significant adoption of embolic coils due to their procedural benefits over liquid embolic agents is expected to restrict the market growth 75
TABLE 15 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY REGION, 2019–2026 (USD MILLION) 76
6.2.1.2 Embolotherapy market for liquid embolic agents, by application 76
TABLE 16 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY APPLICATION, 2019–2026 (USD MILLION) 76
6.2.1.3 Embolotherapy market for liquid embolic agents, by Procedure 77
TABLE 17 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY PROCEDURE, 2019–2026 (USD MILLION) 77
6.2.1.4 Embolotherapy market for liquid embolic agents, by end user 77
TABLE 18 EMBOLOTHERAPY MARKET FOR LIQUID EMBOLIC AGENTS, BY END USER, 2019–2026 (USD MILLION) 77
6.2.2 MICROSPHERES 77
6.2.2.1 Preference for alternative procedures limits the growth of this market segment 77
TABLE 19 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY REGION,
2019–2026 (USD MILLION) 79
6.2.2.2 Embolotherapy market for microspheres, by application 79
TABLE 20 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY APPLICATION,
2019–2026 (USD MILLION) 79
6.2.2.3 Embolotherapy market for microspheres, by Procedure 80
TABLE 21 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY PROCEDURE,
2019–2026 (USD MILLION) 80
6.2.2.4 Embolotherapy market for microspheres, by end user 80
TABLE 22 EMBOLOTHERAPY MARKET FOR MICROSPHERES, BY END USER,
2019–2026 (USD MILLION) 80
6.3 EMBOLIZATION COILS 80
TABLE 23 EMBOLIC COILS OFFERED BY MAJOR MARKET PLAYERS 81
TABLE 24 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 81
TABLE 25 EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY REGION,
2019–2026 (USD MILLION) 82
6.3.1 DETACHABLE COILS 82
6.3.1.1 Detachable coils can be retracted and redeployed a number of times until satisfactory placement is reached, which is a key advantage of this product segment 82
TABLE 26 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY REGION,
2019–2026 (USD MILLION) 83
6.3.1.2 Embolotherapy market for detachable coils, by application 83
TABLE 27 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY APPLICATION, 2019–2026 (USD MILLION) 83
6.3.1.3 Embolotherapy market for detachable coils, by Procedure 84
TABLE 28 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY PROCEDURE,
2019–2026 (USD MILLION) 84
6.3.1.4 Embolotherapy market for detachable coils, by end user 84
TABLE 29 EMBOLOTHERAPY MARKET FOR DETACHABLE COILS, BY END USER,
2019–2026 (USD MILLION) 84
6.3.2 PUSHABLE COILS 84
6.3.2.1 The use of pushable coils increases the risk of non-target vascular blockages, thus restricting their use in various applications 84
TABLE 30 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY REGION,
2019–2026 (USD MILLION) 85
6.3.2.2 Embolotherapy market for pushable coils, by application 85
TABLE 31 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY APPLICATION,
2019–2026 (USD MILLION) 85
6.3.2.3 Embolotherapy market for pushable coils, by Procedure 86
TABLE 32 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY PROCEDURE,
2019–2026 (USD MILLION) 86
6.3.2.4 Embolotherapy market for pushable coils, by end user 86
TABLE 33 EMBOLOTHERAPY MARKET FOR PUSHABLE COILS, BY END USER,
2019–2026 (USD MILLION) 86
6.4 EMBOLIC PLUG SYSTEMS 86
TABLE 34 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY REGION, 2019–2026 (USD MILLION) 87
6.4.1 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION 87
TABLE 35 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY APPLICATION, 2019–2026 (USD MILLION) 87
6.4.2 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE 87
TABLE 36 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY PROCEDURE, 2019–2026 (USD MILLION) 87
6.4.3 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER 88
TABLE 37 EMBOLOTHERAPY MARKET FOR EMBOLIC PLUG SYSTEMS, BY END USER, 2019–2026 (USD MILLION) 88
6.5 DETACHABLE BALLOONS 88
6.5.1 ADVERSE EVENTS ASSOCIATED WITH THE USE OF DETACHABLE BALLOONS SUCH AS BALLOON RUPTURE, FAILURE, OR SHRINKAGE MAY LIMIT THE UTILIZATION OF THIS EMBOLIC DEVICE 88
TABLE 38 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY REGION, 2019–2026 (USD MILLION) 89
6.5.2 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION 89
TABLE 39 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY APPLICATION, 2019–2026 (USD MILLION) 89
6.5.3 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE 89
TABLE 40 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY PROCEDURE, 2019–2026 (USD MILLION) 89
6.5.4 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER 90
TABLE 41 EMBOLOTHERAPY MARKET FOR DETACHABLE BALLOONS, BY END USER, 2019–2026 (USD MILLION) 90
6.6 SUPPORT DEVICES 90
TABLE 42 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 90
TABLE 43 EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY REGION,
2019–2026 (USD MILLION) 91
6.6.1 MICROCATHETERS 91
6.6.1.1 Advancements and regulatory approvals in microcatheter technologies are expected to result in their wider adoption 91
TABLE 44 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY REGION,
2019–2026 (USD MILLION) 91
6.6.1.2 Embolotherapy market for microcatheters, by application 92
TABLE 45 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY APPLICATION,
2019–2026 (USD MILLION) 92
6.6.1.3 Embolotherapy market for microcatheters, by Procedure 92
TABLE 46 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY PROCEDURE,
2019–2026 (USD MILLION) 92
TABLE 47 EMBOLOTHERAPY MARKET FOR MICROCATHETERS, BY END USER,
2019–2026 (USD MILLION) 93
6.6.2 GUIDEWIRES 93
6.6.2.1 Rising adoption of guidewires among medical professionals owing to their procedural benefits is expected to drive market growth 93
TABLE 48 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY REGION,
2019–2026 (USD MILLION) 93
6.6.2.2 Embolotherapy market for guidewires, by application 94
TABLE 49 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY APPLICATION,
2019–2026 (USD MILLION) 94
6.6.2.3 Embolotherapy market for guidewires, by Procedure 94
TABLE 50 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY PROCEDURE,
2019–2026 (USD MILLION) 94
6.6.2.4 Embolotherapy market for guidewires, by end user 95
TABLE 51 EMBOLOTHERAPY MARKET FOR GUIDEWIRES, BY END USER,
2019–2026 (USD MILLION) 95
7 EMBOLOTHERAPY MARKET, BY APPLICATION 96
7.1 INTRODUCTION 97
TABLE 52 EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 97
7.2 ONCOLOGY 97
TABLE 53 EMBOLOTHERAPY MARKET FOR ONCOLOGY, BY TYPE, 2019–2026 98
TABLE 54 EMBOLOTHERAPY MARKET FOR CANCER, BY REGION, 2019–2026 98
7.2.1 LIVER CANCER 98
7.2.1.1 The rising prevalence of liver cancer is expected to drive segment growth 98
TABLE 55 EMBOLOTHERAPY MARKET FOR LIVER CANCER, BY REGION,
2019–2026 (USD MILLION) 99
7.2.2 KIDNEY CANCER 99
7.2.2.1 Preoperative kidney tumor embolization in the treatment of kidney cancer drives the segment growth 99
TABLE 56 EMBOLOTHERAPY MARKET FOR KIDNEY CANCER, BY REGION,
2019–2026 (USD MILLION) 100
7.2.3 LUNG CANCER 100
7.2.3.1 Use of arterial embolotherapy in patients with primary lung cancer to drive the segment growth 100
TABLE 57 EMBOLOTHERAPY MARKET FOR LUNG CANCER, BY REGION,
2019–2026 (USD MILLION) 101
7.2.3.2 The increasing prevalence of breast cancer is a key factor in the higher adoption of embolotherapy among surgeons 101
TABLE 58 EMBOLOTHERAPY MARKET FOR BREAST CANCER, BY REGION,
2019–2026 (USD MILLION) 101
7.2.4 OTHER CANCERS 102
TABLE 59 EMBOLOTHERAPY MARKET FOR OTHER CANCERS, BY REGION,
2019–2026 (USD MILLION) 102
7.3 PERIPHERAL VASCULAR DISEASES 102
7.3.1 RISING ADOPTION OF VASCULAR PLUGS IS A KEY FACTOR DRIVING MARKET GROWTH 102
TABLE 60 EMBOLOTHERAPY MARKET FOR PERIPHERAL VASCULAR DISEASES,
BY REGION, 2019–2026 (USD MILLION) 103
7.4 NEUROLOGY 103
TABLE 61 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY TYPE, 2019–2026 104
TABLE 62 EMBOLOTHERAPY MARKET FOR NEUROLOGY, BY REGION,
2019–2026 (USD MILLION) 104
7.4.1 BRAIN ANEURYSM 104
7.4.1.1 Limited availability of reimbursements across major markets may hinder the market growth 104
TABLE 63 EMBOLOTHERAPY MARKET FOR BRAIN ANEURYSM, BY REGION,
2019–2026 (USD MILLION) 105
7.4.2 CEREBRAL ARTERIOVENOUS MALFORMATION 105
7.4.2.1 Side effects associated with AVM embolization procedures may restrict market growth to a certain extent 105
TABLE 64 EMBOLOTHERAPY MARKET FOR CEREBRAL ARTERIOVENOUS MALFORMATION, BY REGION, 2019–2026 (USD MILLION) 106
7.5 UROLOGY & NEPHROLOGY 106
TABLE 65 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY TYPE,
2019–2026 (USD MILLION) 107
TABLE 66 EMBOLOTHERAPY MARKET FOR UROLOGY & NEPHROLOGY, BY REGION, 2019–2026 (USD MILLION) 107
7.5.1 BENIGN PROSTATIC HYPERPLASIA 107
7.5.1.1 Risks associated with traditional surgery will make patients opt for PAE treatment 107
TABLE 67 EMBOLOTHERAPY MARKET FOR BENIGN PROSTATIC HYPERPLASIA,
BY REGION, 2019–2026 (USD MILLION) 108
7.5.1.2 Advantages offered by the UFE over other techniques is a key factor driving market growth 108
TABLE 68 EMBOLOTHERAPY MARKET FOR UTERINE FIBROIDS, BY REGION,
2019–2026 (USD MILLION) 108
7.5.2 OTHER UROLOGY & NEPHROLOGY APPLICATIONS 109
7.5.2.1 Safety and minimal complication with the use of TAE in this segment will drive the market growth 109
TABLE 69 EMBOLOTHERAPY MARKET FOR OTHER UROLOGY & NEPHROLOGY APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 109
7.6 GASTROINTESTINAL DISORDERS 110
7.6.1 EMBOLIZATION IS A WIDELY ADOPTED PROCEDURE USED TO TREAT LGIB AND UGIB 110
TABLE 70 EMBOLOTHERAPY MARKET FOR GASTROINTESTINAL DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 110
 
8 EMBOLOTHERAPY MARKET, BY PROCEDURE 111
8.1 INTRODUCTION 112
TABLE 71 EMBOLOTHERAPY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION) 112
8.2 TRANSCATHETER ARTERIAL EMBOLIZATION (TAE) 112
8.2.1 THE GROWTH OF THIS SEGMENT IS LARGELY DRIVEN DUE TO THE INCREASING INCIDENCE OF UTERINE FIBROIDS & VASCULAR LESIONS 112
TABLE 72 TRANSCATHETER ARTERIAL EMBOLIZATION MARKET, BY REGION,
2019–2026 (USD MILLION) 113
8.3 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION (TARE)/SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 114
8.3.1 BETTER CLINICAL OUTCOMES & INCREASED CANCER SURVIVAL RATE SUPPORTS THE GROWTH OF THIS SEGMENT 114
TABLE 73 TRANSCATHETER ARTERIAL RADIOEMBOLIZATION MARKET, BY REGION, 2019–2026 (USD MILLION) 115
8.4 TRANSARTERIAL CHEMOEMBOLIZATION (TACE) 115
8.4.1 TACE CAN BE USED TO TREAT TUMORS THAT ARE RELATIVELY LARGER IN SIZE, WHICH CANNOT BE EASILY TREATED BY TUMOR ABLATION 115
TABLE 74 TRANSARTERIAL CHEMOEMBOLIZATION MARKET, BY REGION, 2019–2026 116
9 EMBOLOTHERAPY MARKET, BY END USER 117
9.1 INTRODUCTION 118
TABLE 75 EMBOLOTHERAPY MARKET, BY END USER, 2019–2026 (USD MILLION) 118
9.2 HOSPITALS AND CLINICS 118
9.2.1 RISING INCIDENCE OF TARGET DISEASES TO PROPEL MARKET GROWTH 118
TABLE 76 EMBOLOTHERAPY MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2019–2026 (USD MILLION) 119
9.3 AMBULATORY SURGERY CENTERS 119
9.3.1 INCREASING AVAILABILITY OF REIMBURSEMENTS TO DRIVE THE ADOPTION OF EMBOLOTHERAPY PRODUCTS IN ASCS 119
TABLE 77 EMBOLOTHERAPY MARKET FOR AMBULATORY SURGERY CENTERS,
BY REGION, 2019–2026 (USD MILLION) 120
9.4 OTHER END USERS 120
TABLE 78 EMBOLOTHERAPY MARKET FOR OTHER END USERS, BY REGION,
2019–2026 (USD MILLION) 120
10 EMBOLOTHERAPY MARKET, BY REGION 121
10.1 INTRODUCTION 122
TABLE 79 EMBOLOTHERAPY MARKET, BY REGION, 2019–2026 (USD MILLION) 122
10.2 NORTH AMERICA 123
FIGURE 21 NORTH AMERICA: EMBOLOTHERAPY MARKET SNAPSHOT 123
TABLE 80 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 124
TABLE 81 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 124
TABLE 82 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2019–2026 (USD MILLION) 124
TABLE 83 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 84 NORTH AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 85 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 125
TABLE 86 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 126
TABLE 87 NORTH AMERICA: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 126
10.2.1 US 127
10.2.1.1 Increasing R&D investments in the country drives the market growth 127
TABLE 88 US: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 127
TABLE 89 US: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 90 US: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 128
TABLE 91 US: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 128
10.2.2 CANADA 129
10.2.2.1 The rising prevalence of cancer supports market growth in Canada 129
TABLE 92 CANADA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 129
TABLE 93 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 94 CANADA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 130
TABLE 95 CANADA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 130
10.3 EUROPE 131
TABLE 96 EUROPE: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 131
TABLE 97 EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 131
TABLE 98 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 99 EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 132
TABLE 100 EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 101 EUROPE: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 133
TABLE 102 EUROPE: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 133
TABLE 103 EUROPE: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 134
10.3.1 GERMANY 134
10.3.1.1 Germany is the fastest growing market in Europe 134
TABLE 104 GERMANY: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 135
TABLE 105 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 106 GERMANY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 135
TABLE 107 GERMANY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 136
10.3.2 UK 136
10.3.2.1 The rising geriatric population and the high incidence of chronic diseases support market growth in the UK 136
TABLE 108 UK: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 137
TABLE 109 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 137
TABLE 110 UK: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 137
TABLE 111 UK: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 138
10.3.3 FRANCE 138
10.3.3.1 The growing geriatric population coupled with the increasing number of target surgeries to support market growth in France 138
TABLE 112 FRANCE: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 138
TABLE 113 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 114 FRANCE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 139
TABLE 115 FRANCE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 139
10.3.4 SPAIN 140
10.3.4.1 Increasing government funding for research to support market growth 140
TABLE 116 SPAIN: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 140
TABLE 117 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 140
TABLE 118 SPAIN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 141
TABLE 119 SPAIN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 141
10.3.5 ITALY 141
10.3.5.1 Rising awareness activities to support market growth 141
TABLE 120 ITALY: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 142
TABLE 121 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 122 ITALY: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 142
TABLE 123 ITALY: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 143
10.3.6 REST OF EUROPE 143
TABLE 124 REST OF EUROPE: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 144
TABLE 125 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS,
BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 126 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 127 REST OF EUROPE: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 145
10.4 ASIA PACIFIC 145
FIGURE 22 ASIA PACIFIC: EMBOLOTHERAPY MARKET SNAPSHOT 146
TABLE 128 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 147
TABLE 129 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 147
TABLE 130 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 131 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 132 ASIA PACIFIC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 133 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 149
TABLE 134 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 149
TABLE 135 ASIA PACIFIC: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 150
10.4.1 JAPAN 150
10.4.1.1 Presence of universal healthcare reimbursement scenario and growing geriatric population—key factors driving market growth 150
TABLE 136 JAPAN: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 151
TABLE 137 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 138 JAPAN: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 151
TABLE 139 JAPAN: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 152
10.4.2 CHINA 152
10.4.2.1 Increasing patient pool and government initiatives for healthcare development supports market growth 152
TABLE 140 CHINA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 153
TABLE 141 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 142 CHINA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 153
TABLE 143 CHINA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 154
10.4.3 INDIA 154
10.4.3.1 Ongoing modernization and infrastructure development in India to support the market growth for embolotherapy 154
TABLE 144 INDIA: EMBOLOTHERAPY MARKET, BY PRODUCT, 2019–2026 (USD MILLION) 155
TABLE 145 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 155
TABLE 146 INDIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 155
TABLE 147 INDIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 156
10.4.4 SOUTH KOREA 156
10.4.4.1 Rising R&D and promising clinical trials in the country to positively impact market growth 156
TABLE 148 SOUTH KOREA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 156
TABLE 149 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 150 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 157
TABLE 151 SOUTH KOREA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 157
10.4.5 AUSTRALIA 158
10.4.5.1 Rising research investments and awareness campaigns are the key factors supporting market growth in Australia 158
TABLE 152 AUSTRALIA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 158
TABLE 153 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 154 AUSTRALIA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 159
TABLE 155 AUSTRALIA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 159
10.4.6 REST OF ASIA PACIFIC 159
TABLE 156 REST OF APAC: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 160
TABLE 157 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 158 REST OF APAC: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 160
TABLE 159 REST OF APAC: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 161
10.5 LATIN AMERICA 161
TABLE 160 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 161
TABLE 161 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 162
TABLE 162 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 163 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 162
TABLE 164 LATIN AMERICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 163
TABLE 165 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 163
TABLE 166 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 164
TABLE 167 LATIN AMERICA: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 164
10.5.1 BRAZIL 164
10.5.1.1 Brazil is a key market in Latin America owing to the modernization of healthcare facilities 164
TABLE 168 BRAZIL: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 165
TABLE 169 BRAZIL: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 170 BRAZIL : EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 165
TABLE 171 BRAZIL: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE,
2019–2026 (USD MILLION) 166
10.5.2 MEXICO 166
10.5.2.1 Availability of advanced care and increasing awareness programs are driving market growth in Mexico 166
TABLE 172 MEXICO: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 167
TABLE 173 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 174 MEXICO: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE,
2019–2026 (USD MILLION) 167
TABLE 175 MEXICO: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 168
10.5.3 REST OF LATIN AMERICA 168
TABLE 176 REST OF LATAM: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 168
TABLE 177 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 178 REST OF LATAM: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS, BY TYPE, 2019–2026 (USD MILLION) 169
TABLE 179 REST OF LATAM: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES,
BY TYPE, 2019–2026 (USD MILLION) 169
10.6 MIDDLE EAST & AFRICA 170
10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN THE MEA 170
TABLE 180 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PRODUCT,
2019–2026 (USD MILLION) 171
TABLE 181 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC AGENTS, BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 182 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR EMBOLIC COILS,
BY TYPE, 2019–2026 (USD MILLION) 171
TABLE 183 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET FOR SUPPORT DEVICES, BY TYPE, 2019–2026 (USD MILLION) 172
TABLE 184 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY APPLICATION, 2019–2026 (USD MILLION) 172
TABLE 185 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY PROCEDURE,
2019–2026 (USD MILLION) 173
TABLE 186 MIDDLE EAST & AFRICA: EMBOLOTHERAPY MARKET, BY END USER,
2019–2026 (USD MILLION) 173
11 COMPETITIVE LANDSCAPE 174
11.1 OVERVIEW 174
FIGURE 23 KEY DEVELOPMENTS IN THE EMBOLOTHERAPY MARKET FROM 2017 TO 2020 174
11.2 GLOBAL MARKET SHARE ANALYSIS 175
11.2.1 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS (2019) 175
FIGURE 24 GLOBAL EMBOLOTHERAPY MARKET SHARE ANALYSIS, BY KEY PLAYER (2020) 175
11.3 COMPETITIVE LEADERSHIP MAPPING 175
11.3.1 STARS 176
11.3.2 EMERGING LEADERS 176
11.3.3 PERVASIVE 176
11.3.4 PARTICIPANTS 176
FIGURE 25 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 177
FIGURE 26 EMBOLOTHERAPY MARKET: COMPETITIVE LEADERSHIP MAPPING (SME/START-UPS) 178
11.4 COMPETITIVE SCENARIO 179
11.4.1 PRODUCT LAUNCHES 179
TABLE 187 EMBOLOTHERAPY MARKET: PRODUCT LAUNCHES
AND APPROVALS, 2017–2020 179
11.4.2 EXPANSIONS 180
TABLE 188 EMBOLOTHERAPY MARKET: EXPANSIONS, 2017–2020 180
11.4.3 ACQUISITIONS 180
TABLE 189 EMBOLOTHERAPY MARKET: ACQUISITIONS, 2017–2020 180
12 COMPANY PROFILES 181
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1 KEY PLAYERS 181
12.1.1 BOSTON SCIENTIFIC CORPORATION 181
TABLE 190 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW 181
FIGURE 27 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 182
12.1.2 MERIT MEDICAL SYSTEMS 185
TABLE 191 MERIT MEDICAL SYSTEMS: BUSINESS OVERVIEW 185
FIGURE 28 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT 186
12.1.3 TERUMO CORPORATION 188
TABLE 192 TERUMO CORPORATION: BUSINESS OVERVIEW 188
FIGURE 29 TERUMO CORPORATION: COMPANY SNAPSHOT 189
12.1.4 MEDTRONIC PLC 192
TABLE 193 MEDTRONIC PLC: BUSINESS OVERVIEW 192
FIGURE 30 MEDTRONIC PLC: COMPANY SNAPSHOT 192
12.1.5 ABBOTT LABORATORIES 195
TABLE 194 ABBOTT LABORATORIES: BUSINESS OVERVIEW 195
FIGURE 31 ABBOTT LABORATORIES: COMPANY SNAPSHOT 196
12.1.6 DEPUY SYNTHES (J&J MEDICAL DEVICES) 197
TABLE 195 DEPUY SYNTHES: BUSINESS OVERVIEW 197
FIGURE 32 JOHNSON & JOHNSON: COMPANY SNAPSHOT 198
12.1.7 COOK MEDICAL 200
TABLE 196 COOK MEDICAL: BUSINESS OVERVIEW 200
12.1.8 BALT 202
TABLE 197 BALT: BUSINESS OVERVIEW 202
12.1.9 SIRTEX MEDICAL LIMITED (PART OF CDH INVESTMENTS) 204
TABLE 198 SIRTEX MEDICAL LIMITED: BUSINESS OVERVIEW 204
12.1.10 KANEKA CORPORATION 205
TABLE 199 KANEKA CORPORATION: BUSINESS OVERVIEW 205
FIGURE 33 KANEKA CORPORATION: COMPANY SNAPSHOT 206
12.1.11 STRYKER CORPORATION 208
TABLE 200 STRYKER CORPORATION: BUSINESS OVERVIEW 208
FIGURE 34 STRYKER CORPORATION: COMPANY SNAPSHOT 208
12.2 OTHER PLAYERS 210
12.2.1 PENUMBRA, INC. 210
TABLE 201 PENUMBRA, INC.: BUSINESS OVERVIEW 210
FIGURE 35 PENUMBRA, INC.: COMPANY SNAPSHOT 211
12.2.2 MERIL LIFE SCIENCES PVT., LTD. 213
TABLE 202 MERIL LIFE SCIENCES PVT., LTD.: BUSINESS OVERVIEW 213
12.2.3 ACANDIS GMBH 214
TABLE 203 ACANDIS GMBH: BUSINESS OVERVIEW 214
12.2.4 CARDIVA MEDICAL INC. (PART OF HAEMONETICS) 215
TABLE 204 CARDIVA MEDICAL INC.: BUSINESS OVERVIEW 215
12.2.5 SHAPE MEMORY MEDICAL, INC. 216
TABLE 205 SHAPE MEMORY MEDICAL, INC..: BUSINESS OVERVIEW 216
12.2.6 ARTIO MEDICAL, INC. 217
TABLE 206 ARTIO MEDICAL, INC.: BUSINESS OVERVIEW 217
12.2.7 RAPID MEDICAL 218
TABLE 207 RAPID MEDICAL: BUSINESS OVERVIEW 218
12.2.8 IMBIOTECHNOLOGIES LTD. 219
TABLE 208 IMBIOTECHNOLOGIES LTD.: BUSINESS OVERVIEW 219
12.2.9 EMBOLINE, INC. 221
TABLE 209 EMBOLINE, INC.: BUSINESS OVERVIEW 221
*Details on Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX 222
13.1 DISCUSSION GUIDE 222
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
13.3 AVAILABLE CUSTOMIZATIONS 229
13.4 RELATED REPORTS 229
13.5 AUTHOR DETAILS 230

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127